James T Rosenbaum

List of Publications by Year in Descending Order

61 papers	1,488 citations	21 h-index	37 g-index
64 ext. papers	1,828 ext. citations	7.2 avg, IF	4.21 L-index

#	Paper	IF	Citations
61	Letter to the Editor Reply Regarding ACR White Paper on Antimalarials and Cardiac Toxicity: Suggested Amendments to Future Directions.. *Arthritis and Rheumatology*, **2022**,	9.5	
60	Corneal Endothelial Transplantation in Uveitis: Incidence and Risk Factors. *American Journal of Ophthalmology*, **2021**,	4.9	1
59	American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity. *Arthritis and Rheumatology*, **2021**, 73, 2151-2160	9.5	2
58	Tofacitinib as a Steroid-Sparing Therapy in Pulmonary Sarcoidosis, an Open-Label Prospective Proof-of-Concept Study. *Lung*, **2021**, 199, 147-153	2.9	7
57	American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 Joint Statement on Hydroxychloroquine Use With Respect to Retinal Toxicity. *Arthritis and Rheumatology*, **2021**, 73, 908-911	9.5	10
56	HLA-B27 is associated with reduced disease activity in axial spondyloarthritis. *Scientific Reports*, **2021**, 11, 12331	4.9	0
55	Identifying RNA Biomarkers and Molecular Pathways Involved in Multiple Subtypes of Uveitis. *American Journal of Ophthalmology*, **2021**, 226, 226-234	4.9	3
54	The Effect of HLA-B27 on Susceptibility and Severity of COVID-19. *Journal of Rheumatology*, **2021**, 48, 621-622	4.1	11
53	Revising the Diagnosis of Idiopathic Uveitis by Peripheral Blood Transcriptomics. *American Journal of Ophthalmology*, **2021**, 222, 15-23	4.9	4
52	Risk of Cataract in Intermediate Uveitis. *American Journal of Ophthalmology*, **2021**, 229, 200-209	4.9	2
51	Molecular and Cellular Characterization of Pyoderma Gangrenosum: Implications for the Use of Gene Expression. *Journal of Investigative Dermatology*, **2021**,	4.3	1
50	The Interplay Between COVID-19 and Spondyloarthritis or Its Treatment. *Journal of Rheumatology*, **2021**,	4.1	3
49	Exudative Retinal Detachment in Ocular Inflammatory Diseases: Risk and Predictive Factors. *American Journal of Ophthalmology*, **2020**, 218, 279-287	4.9	8
48	Factors Predictive of Remission of Chronic Anterior Uveitis. *Ophthalmology*, **2020**, 127, 826-834	7.3	3
47	HLA-A alleles including HLA-A29 affect the composition of the gut microbiome: a potential clue to the pathogenesis of birdshot retinochoroidopathy. *Scientific Reports*, **2020**, 10, 17636	4.9	3
46	Case 8-2019: A 58-Year-Old Woman with Vision Loss, Headaches, and Oral Ulcers. *New England Journal of Medicine*, **2019**, 380, 1062-1071	59.2	0
45	Comparison Between Methotrexate and Mycophenolate Mofetil Monotherapy for the Control of Noninfectious Ocular Inflammatory Diseases. *American Journal of Ophthalmology*, **2019**, 208, 68-75	4.9	14

44	Gene Expression Pathways across Multiple Tissues in Antineutrophil Cytoplasmic Antibody-associated Vasculitis Reveal Core Pathways of Disease Pathology. *Journal of Rheumatology*, **2019**, 46, 609-615	4.1	7
43	Reclassifying Idiopathic Uveitis: Lessons From a Tertiary Uveitis Center. *American Journal of Ophthalmology*, **2019**, 198, 193-199	4.9	8
42	Uveitis and Juvenile Psoriatic Arthritis or Psoriasis. *American Journal of Ophthalmology*, **2018**, 185, 68-74	4.9	11
41	The Microbiome and Systemic Lupus Erythematosus. *New England Journal of Medicine*, **2018**, 378, 2236-2237	59.1	14
40	Risk of Ocular Hypertension in Adults with Noninfectious Uveitis. *Ophthalmology*, **2017**, 124, 1196-1208	7.3	15
39	Retinal vasculitis. *Current Opinion in Rheumatology*, **2016**, 28, 228-35	5.3	54
38	Remission of Intermediate Uveitis: Incidence and Predictive Factors. *American Journal of Ophthalmology*, **2016**, 164, 110-7.e2	4.9	21
37	Molecular diagnosis: Implications for ophthalmology. *Progress in Retinal and Eye Research*, **2016**, 50, 25-32	20.5	6
36	Gut Microbial Alterations Associated With Protection From Autoimmune Uveitis **2016**, 57, 3747-58		102
35	Molecular diagnosis of orbital inflammatory disease. *Experimental and Molecular Pathology*, **2015**, 98, 225-9	4.4	26
34	Parallel Gene Expression Changes in Sarcoidosis Involving the Lacrimal Gland, Orbital Tissue, or Blood. *JAMA Ophthalmology*, **2015**, 133, 770-7	3.9	22
33	Orbital pseudotumor can be a localized form of granulomatosis with polyangiitis as revealed by gene expression profiling. *Experimental and Molecular Pathology*, **2015**, 99, 271-8	4.4	27
32	The Risk of Intraocular Pressure Elevation in Pediatric Noninfectious Uveitis. *Ophthalmology*, **2015**, 122, 1987-2001	7.3	34
31	Blau syndrome-associated Nod2 mutation alters expression of full-length NOD2 and limits responses to muramyl dipeptide in knock-in mice. *Journal of Immunology*, **2015**, 194, 349-57	5.3	27
30	The Role of the Immune Response in the Pathogenesis of Thyroid Eye Disease: A Reassessment. *PLoS ONE*, **2015**, 10, e0137654	3.7	10
29	Fibrosis, gene expression and orbital inflammatory disease. *British Journal of Ophthalmology*, **2015**, 99, 1424-9	5.5	19
28	Periocular corticosteroid injections in uveitis: effects and complications. *Ophthalmology*, **2014**, 121, 2275-86	7.3	94
27	Rituximab therapy for refractory scleritis: results of a phase I/II dose-ranging, randomized, clinical trial. *Ophthalmology*, **2014**, 121, 1885-91	7.3	67

26	Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema. *Ophthalmology*, **2014**, 121, 588-95.e1	7.3	46
25	The course of retinal vasculitis. *British Journal of Ophthalmology*, **2014**, 98, 785-9	5.5	27
24	Factors predictive of remission of new-onset anterior uveitis. *Ophthalmology*, **2014**, 121, 778-84	7.3	11
23	IgG4 immunostaining and its implications in orbital inflammatory disease. *PLoS ONE*, **2014**, 9, e109847	3.7	35
22	Risk of choroidal neovascularization among the uveitides. *American Journal of Ophthalmology*, **2013**, 156, 468-477.e2	4.9	71
21	The expression of STAT-1 and phosphorylated STAT-1 in conjunctival granulomas. *Ocular Immunology and Inflammation*, **2010**, 18, 261-4	2.8	10
20	Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. *Arthritis and Rheumatism*, **2001**, 45, 252-7		293
19	Intraocular in vivo imaging of activated T-lymphocytes expressing green-fluorescent protein after stimulation with endotoxin **2001**, 239, 609-12		9
18	Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease **2001**, 45, 252		5
17	Anti-rat ICAM-1 antibody does not influence the course of experimental melanin-induced uveitis. *Current Eye Research*, **2000**, 21, 906-12	2.9	11
16	The tyranny of the anecdote: Waldenstrom's macroglobulinemia and scleritis. *Ocular Immunology and Inflammation*, **2000**, 8, 111-113	2.8	4
15	Management of immune-mediated uveitis. *BioDrugs*, **2000**, 13, 9-20	7.9	3
14	Anterior uveitis: clinical and research perspectives. *Seminars in Immunopathology*, **1999**, 21, 135-45		2
13	Intravitreally injected platelet activating factor induces retinitis in experimental animals. *Current Eye Research*, **1999**, 18, 342-8	2.9	6
12	Anterior uveitis: clinical and research perspectives. *Seminars in Immunopathology*, **1999**, 21, 135-145		
11	Drug-induced uveitis. Incidence, prevention and treatment. *Drug Safety*, **1997**, 17, 197-207	5.1	52
10	Myocardial infarction as a complication of immunoglobulin therapy. *Arthritis and Rheumatism*, **1997**, 40, 1732-1733		
9	Myocardial infarction as a complication of immunoglobulin therapy. *Arthritis and Rheumatism*, **1997**, 40, 1732-1733		33

8	Increased expression of basic fibroblast growth factor in hyperoxic-injured mouse lung. *Journal of Cellular Biochemistry*, **1994**, 56, 536-43	4.7	13
7	Ocular inflammatory effects of intravitreally injected interleukin-2. *Current Eye Research*, **1993**, 12, 649-54	2.9	12
6	Efficacy of antibodies to adhesion molecules, CD11a or CD18, in rabbit models of uveitis. *Current Eye Research*, **1993**, 12, 827-31	2.9	27
5	Retinal pigment epithelial cells produce interleukin-1 beta and granulocyte-macrophage colony-stimulating factor in response to interleukin-1 alpha. *Current Eye Research*, **1993**, 12, 205-12	2.9	51
4	Expression of growth factor mRNA in rabbit PVR model systems. *Current Eye Research*, **1992**, 11, 1031-9	2.9	23
3	Cultured human retinal pigment epithelial cells express basic fibroblast growth factor and its receptor. *Current Eye Research*, **1989**, 8, 1029-37	2.9	91
2	Retinal pigment epithelial cells secrete substances that are chemotactic for monocytes. *Current Eye Research*, **1987**, 6, 793-800	2.9	17
1	Ophthalmic Risks and Complications Associated with the Treatment of Systemic Vasculitis495-504		